|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Alderley_Park
|
|
gptkbp:business_model
|
biopharmaceuticals
contract research
|
|
gptkbp:ceo
|
Duncan Peyton
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
MRx0005 for inflammatory bowel disease
MRx0005 for lupus
MRx0005 for multiple sclerosis
MRx0005 for psoriasis
MRx0005 for rheumatoid arthritis
MRx0005 in autoimmune patients
MRx0518 for breast cancer
MRx0518 for colorectal cancer
MRx0518 for lung cancer
MRx0518 for melanoma
MRx0518 for prostate cancer
MRx0518 in cancer patients
|
|
gptkbp:collaboration
|
gptkb:Astra_Zeneca
gptkb:Pfizer
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
|
|
gptkbp:focus
|
microbiome therapeutics
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:founder
|
Duncan Peyton
|
|
gptkbp:funding
|
gptkb:Series_A
gptkb:Series_B
Series C
|
|
gptkbp:headquarters
|
gptkb:Leeds,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
4 D Pharma
|
|
gptkbp:invention
|
therapeutic vaccines
microbiome-based therapies
|
|
gptkbp:investment
|
£20 million
|
|
gptkbp:marketing_strategy
|
partnerships
licensing agreements
|
|
gptkbp:partnership
|
gptkb:University_of_Leeds
gptkb:University_of_Oxford
|
|
gptkbp:product
|
gptkb:MRx0005
gptkb:MRx0518
|
|
gptkbp:publications
|
gptkb:Journal_of_Immunology
gptkb:Clinical_Cancer_Research
gptkb:Nature
gptkb:Science
gptkb:Nature_Reviews_Immunology
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research_areas
|
oncology
immunology
|
|
gptkbp:research_focus
|
respiratory diseases
gastrointestinal diseases
metabolic diseases
|
|
gptkbp:stock_exchange
|
gptkb:London_Stock_Exchange
|
|
gptkbp:target_market
|
gptkb:cancer_treatment
autoimmune diseases
|
|
gptkbp:technology
|
Live Biotherapeutics
|
|
gptkbp:bfsParent
|
gptkb:Agenus_Inc.
|
|
gptkbp:bfsLayer
|
5
|